Rosuvastatin
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Rosuvastatin: Cholesterol-ester transfer protein deficiency
One-Sentence Summary
Rosuvastatin is a statin originally used to treat high cholesterol and related conditions, including hyperlipidemia, homozygous familial hypercholesterolemia and atherosclerosis. The TxGNN model predicts it may be effective for cholesterol-ester transfer protein (CETP) deficiency. However, 0 clinical trials and 0 publications currently support this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Cholesterol-ester transfer protein deficiency |
| TxGNN Prediction Score | 0.9954 |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, rosuvastatin is a statin (an HMG-CoA reductase inhibitor). It lowers LDL cholesterol (LDL-C) by reducing cholesterol synthesis in the liver, and it is well established for hyperlipidemia and familial hypercholesterolemia.
CETP deficiency is also a disorder of lipid metabolism. It raises HDL cholesterol and lowers LDL cholesterol. This shared lipid-metabolism territory is probably why the model scored the pairing so highly.
The mechanistic link is speculative, though. Rosuvastatin already lowers LDL-C, and CETP deficiency tends to lower it as well. There is no clear unmet need that a statin would address in this condition. No clinical or literature evidence was found to support the prediction, so the high score should be read as a model signal, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Rosuvastatin has 20 valid single-ingredient licences in Canada. Dosage form and approved-indication text are not available for these licences. The first 5 are listed below.
| DIN | Product Name |
|---|---|
| 02378531 | PMS-ROSUVASTATIN |
| 02413108 | MAR-ROSUVASTATIN |
| 02378566 | PMS-ROSUVASTATIN |
| 02536625 | NRA-ROSUVASTATIN TABLETS |
| 02337975 | APO-ROSUVASTATIN |
Safety Considerations
Label-based warnings and contraindications are not available in the data compiled for this report. Please refer to the package insert for these.
- Contraindication signals (from the TxGNN knowledge graph, not label text): liver disease, gallbladder disease, hypothyroidism, myxedema, congenital hypothyroidism, myopathy, muscular disease, skeletal muscle disease, familial periodic paralysis, substance abuse/dependence, rhabdomyolysis, nodular fasciitis, injury, proteinuria.
- Drug Interactions: 100 interactions were identified, of which the first 20 were reviewed.
- Major: fenofibrate, atazanavir.
- Moderate (examples): atorvastatin, ezetimibe, bempedoic acid, amiodarone, paclitaxel, alpelisib, apalutamide, ethanol.
- Minor: levonorgestrel, norethisterone, desogestrel.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9954) but no supporting trials or publications. The mechanistic link is speculative, and CETP deficiency has no clear unmet need that a statin would address.
To proceed, the following is needed:
- Any clinical, genetic or mechanistic evidence for statin use in CETP deficiency, such as case series or lipid-response data.
- A clear clinical rationale for what benefit rosuvastatin would add in this condition.
- Mechanism of action data and package-insert warnings and contraindications to support safety screening.
- Review of the major interactions (fenofibrate, atazanavir) and the myopathy and liver-related contraindication signals, if the project advances.
Context from other predictions: HIV infection (L2) has Phase 2 trial evidence. It concerns cardiovascular and metabolic comorbidity and would be an adjunctive use, not treatment of HIV itself.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.